Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer

Inclusion Criteria: * Patients must have histologically or cytologically confirmed inoperable or metastatic adenocarcinoma of the stomach or lower third of the oesophagus refractory or intolerable to standard therapy. * Patients must have measurable or evaluable disease. * Age \>= 201years * ECOG performance status of 0 to 2 * Life expectancy at least 3 months * Patients must have normal organ and marrow function as defined below: * absolute neutrophil count \>=1,500/mcL * platelets \>=100,000/mcL * total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) \<=2.5 X institutional upper limit of * Normal creatinine within normal institutional limits * Patients must be HLA-A\*2402 * Patients must have recover from all reversible treatment toxicity from prior chemotherapy, radiotherapy or surgery. * The effects of OTSGC-A24 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients receiving any other investigational agents. * History of significant gastrointestinal bleeding that required intervention within the prior 1 month is ineligible; inherited bleeding diathesis or coagulopathy. * Serious non healing wound and peptic ulcer disease * Previous history of intestinal perforation * Invasive procedures defined as follows (Insertion of a vascular access device is not considered major/minor surgery): * Major surgical procedure, open biopsy or significant traumatic injury =28 days prior to -registration * Anticipation of need for major surgical procedures during the course of the study * Core biopsy \<=7 days * Minor surgery \<=2 weeks * Symptomatic CNS metastasis * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension (systolic \>150 mmHg and/or diastolic \>100 mmHg), symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction/cerebrovascular event (\<=6 months prior to study entry), cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, long term systemic immunosuppressant or corticosteroid. * Women who are breast-feeding or pregnant are excluded from this study